Research agreement · November 19, 2026 · Merck (MRK)

Merck and Isomorphic Labs Announce Oncology Research Collaboration

Reported agreement facts

Merck’s November 19 announcement describes a collaboration to discover small-molecule therapeutic candidates against an oncology target. Isomorphic Labs will use its IsoDDE drug-design engine and selected Merck data to make computational predictions and deliver molecular designs.

Merck will handle preclinical and clinical development, manufacturing and commercialization of any resulting products. Isomorphic Labs receives an upfront payment, eligibility for milestone payments and tiered sales royalties, plus an option to co-fund development for higher royalties. The release does not state payment amounts or royalty rates.

Analysis

Our interpretation is that the agreement combines computational design with Merck’s development infrastructure. The allocation of responsibilities is concrete; successful candidate discovery, trial outcomes and commercial products remain uncertain.

Without disclosed economics or program results, the announcement alone cannot establish a financial return or a direction for Merck shares. It reports a research agreement, rather than clinical evidence of benefit. We make no buy or sell recommendation.

Related reading

See the separate nemtabrutinib program update, browse the market-report index, or return to the clock dashboard.